These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21118395)

  • 1. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study.
    Miwa H; Inoue K; Ashida K; Kogawa T; Nagahara A; Yoshida S; Tano N; Yamazaki Y; Wada T; Asaoka D; Fujita T; Tanaka J; Shimatani T; Manabe N; Oshima T; Haruma K; Azuma T; Yokoyama T;
    Aliment Pharmacol Ther; 2011 Feb; 33(3):323-32. PubMed ID: 21118395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying.
    Futagami S; Iwakiri K; Shindo T; Kawagoe T; Horie A; Shimpuku M; Tanaka Y; Kawami N; Gudis K; Sakamoto C
    J Gastroenterol; 2010 Apr; 45(4):413-21. PubMed ID: 19997942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease.
    Yamaji Y; Isomura Y; Yoshida S; Yamada A; Hirata Y; Koike K
    J Dig Dis; 2014 Sep; 15(9):469-76. PubMed ID: 24957863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
    Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
    Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
    Wada T; Sasaki M; Kataoka H; Tanida S; Itoh K; Ogasawara N; Oshima T; Togawa S; Kubota E; Yamada T; Mori Y; Fujita F; Ohara H; Nakao H; Sobue S; Joh T; Itoh M
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():2-9. PubMed ID: 15943840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors.
    Miner PB; McKean LA; Gibb RD; Erasala GN; Ramsey DL; McRorie JW
    Aliment Pharmacol Ther; 2010 Apr; 31(8):846-51. PubMed ID: 20146702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed combination of hyaluronic acid and chondroitin-sulphate oral formulation in a randomized double blind, placebo controlled study for the treatment of symptoms in patients with non-erosive gastroesophageal reflux.
    Palmieri B; Merighi A; Corbascio D; Rottigni V; Fistetto G; Esposito A
    Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3272-8. PubMed ID: 24379055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group.
    Wiklund I; Bardhan KD; Müller-Lissner S; Bigard MA; Bianchi Porro G; Ponce J; Hosie J; Scott M; Weir D; Fulton C; Gillon K; Peacock R
    Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):19-27. PubMed ID: 9615259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial.
    Boeckxstaens GE; Beaumont H; Hatlebakk JG; Silberg DG; Björck K; Karlsson M; Denison H
    Gut; 2011 Sep; 60(9):1182-8. PubMed ID: 21402616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study.
    Suzuki T; Matsushima M; Masui A; Tsuda S; Imai J; Nakamura J; Tsukune Y; Uchida T; Yuhara H; Igarashi M; Koike J; Mine T
    World J Gastroenterol; 2015 Apr; 21(16):5023-31. PubMed ID: 25945018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
    Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial: roxatidine vs omeprazole for non-erosive reflux disease.
    Nakamura K; Akiho H; Ochiai T; Motomura Y; Higuchi N; Okamoto R; Matsui N; Yasuda D; Akahoshi K; Kabemura T; Ihara E; Harada N; Ito T; Takayanagi R
    Hepatogastroenterology; 2010; 57(99-100):497-500. PubMed ID: 20698216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease.
    Lee ES; Kim N; Lee SH; Park YS; Kim JW; Jeong SH; Lee DH; Jung HC; Song IS
    Aliment Pharmacol Ther; 2009 Jul; 30(2):154-64. PubMed ID: 19392871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease.
    Kinoshita Y; Ashida K; Hongo M;
    Aliment Pharmacol Ther; 2011 Jan; 33(2):213-24. PubMed ID: 21083596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of double dose of omeprazole on the course of angina pectoris and treadmill stress test in patients with coronary artery disease--a randomised, double-blind, placebo controlled, crossover trial.
    Budzyński J; Kłopocka M; Pulkowski G; Suppan K; Fabisiak J; Majer M; Swiatkowski M
    Int J Cardiol; 2008 Jul; 127(2):233-9. PubMed ID: 17689732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of pre-endoscopy proton pump inhibitor use on the classification of non-erosive reflux disease and erosive oesophagitis.
    Gaddam S; Wani S; Ahmed H; Maddur P; Hall SB; Gupta N; Puli SR; Higbee A; Rastogi A; Bansal A; Sharma P
    Aliment Pharmacol Ther; 2010 Nov; 32(10):1266-74. PubMed ID: 20955446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omeprazole improves peak expiratory flow rate and quality of life in asthmatics with gastroesophageal reflux.
    Levin TR; Sperling RM; McQuaid KR
    Am J Gastroenterol; 1998 Jul; 93(7):1060-3. PubMed ID: 9672330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial.
    Björnsson E; Abrahamsson H; Simrén M; Mattsson N; Jensen C; Agerforz P; Kilander A
    Aliment Pharmacol Ther; 2006 Sep; 24(6):945-54. PubMed ID: 16948806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
    Bautista J; Fullerton H; Briseno M; Cui H; Fass R
    Aliment Pharmacol Ther; 2004 May; 19(10):1123-30. PubMed ID: 15142202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.